Fig. 2From: Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry a: Overall Survival for mRCC Patients with or without Immune-Related Adverse Events, Comparing Group I (no irAE/or irAE before IL-2) with Group II (irAE During/After IL-2) (Autoimmune Disease = irAE), p = 0.0302. b: Overall Survival in Patients with mRCC, comparing Group I with Group II, removing those with irAE due to CPI. (Autoimmune Disease = irAE), p = 0.0302Back to article page